Gliotoxin from the marine fungus  induces apoptosis in HT1080 fibrosarcoma cells by downregulating NF-κB by unknown
Kim and Park Fisheries and Aquatic Sciences  (2016) 19:35 
DOI 10.1186/s41240-016-0036-6RESEARCH ARTICLE Open AccessGliotoxin from the marine fungus
Aspergillus fumigatus induces apoptosis
in HT1080 fibrosarcoma cells by
downregulating NF-κB
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Gliotoxin has been recognized as an immunosuppressive agent for a long time. Recently, it was reported to have
antitumor properties. However, the mechanisms by which it inhibits tumors remain unclear. Here, we showed that
gliotoxin isolated from the marine fungus Aspergillus fumigatus inhibited proliferation and induced apoptosis in
HT1080 human fibrosarcoma cells. Gliotoxin repressed phosphorylation-dependent degradation of IκB-α, an antagonist
of nuclear factor kappa B (NF-κB), which is a known tumor-promoting factor. This coincided with a decrease in nuclear
import of NF-κB, suggesting its signaling activity was impaired. Moreover, gliotoxin increased intracellular reactive
oxygen species (ROS). Since ROS have been known to inhibit NF-κB, this may also contribute to gliotoxin’s
antitumorigenic effects. These results suggest that gliotoxin suppressed the activation of NF-κB by inhibiting
phosphorylation and degradation of IκB-α and by increasing ROS, which resulted in apoptosis of HT1080 cells.
Cumulatively, gliotoxin is a promising candidate antagonist of NF-κB, and it should be investigated for its possible
use as a selective inhibitor of human fibrosarcoma cells.
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Fungal secondary metabolites are chemically diverse,
and some display pharmaceutical potential as inhibitors
of inflammation, cytotoxicity, and cancer (Shao et al.
2011; Wei et al. 2010). Gliotoxin, a member of the epi-
polythiodioxopiperazine family of secondary metabolites,
is characterized by a disulfide bond across a piperazine
ring. It has been isolated from several species of fungi,
including the human pathogen Aspergillus (Waring
et al. 1995). Gliotoxin is known to possess immunosup-
pressive properties, and it causes apoptosis in immune
cells including neutrophils, eosinophils, macrophages,
and thymocytes (Sutton et al. 1994; Pahl et al. 1996;
Lopez-Franco et al. 2002). Gliotoxin’s immunosuppres-
sive properties result from its inhibition of nuclear factor
kappa B (NF-κB) because it represses proteasome-
mediated degradation of the NF-κB antagonist, IκB-α* Correspondence: parksj@pknu.ac.kr
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enters the redox cycle and transitions between reduced
and oxidized forms after uptake into cells. Reactive oxygen
species (ROS) are produced as a by-product, and this
induces DNA damage and apoptosis in immune cells
(Harms et al. 2015). ROS have also been reported to in-
hibit NF-κB through direct oxidation (Toledano and
Leonard 1991; Nowak et al. 2008). In this regard, the
role of gliotoxin in regulating NF-κB and ROS has
focused on immunological therapeutic applications.
However, recent publications suggest that gliotoxin has
antitumor properties (Kweon et al. 2003; Bhatnagar and
Kim 2015), although the mechanistic details remain
unclear. In the present study, we investigated the anti-
proliferative effects of gliotoxin on HT1080 human
fibrosarcoma cells. We found that gliotoxin from the
marine fungus Aspergillus fumigatu regulates prolifera-
tion of HT1080 cells by inducing apoptosis. This cyto-
toxicity was related to the inactivation of NF-κB and an
increase in intracellular ROS.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Materials and chemicals
Gliotoxin from the marine fungus Aspergillus fumigatus
was obtained as described by Bhatnagar and Kim (2015).
Briefly, A. fumigatus was isolated from the surface of mar-
ine green algae, which were collected in Cheongsapo,
Busan, Republic of Korea. The fungal strain was cultured
in YPGA media containing 0.1 % yeast extract, 2 %
peptone, 1 % glucose, 2 % agar, 60 % seawater, and 40 %
distilled water. The fermentation broth was extracted
(2.3 g) with ethyl acetate (EtOAc, 1:1.5 v/v; broth-EtOAc,
1:1 v/v). The extract was fractionated by silica gel chroma-
tography (n-hexane-EtOAc, 100 %:0 %; CH2Cl2-methyl
alcohol (MeOH), 1:1), ODS column chromatography
(H2O-MeOH, 100 %:100 %), and Sephadex LH-20 column
chromatography (H2O-MeOH, 100 %:100 %). High-
performance liquid chromatography (HPLC) using a YMC
ODS-A column (250 mm× 10 mm I.D., S-5 μm, 12 nm,
MeOH) yielded purified gliotoxin (5.2 mg). The structure
and molecular formula of gliotoxin was ascertained using
1H and 13C nuclear magnetic resonance (NMR), as well
as low-resolution electron impact mass spectrometry
(LREI-MS) data. 1H NMR spectrum (DMSO-d6,
400 MHz): 3.44 (1H, dd, J = 4.8, H-3a), 4.28 (1H, dd, J =
9.9, H-3a), 4.39 (1H, dd, J = 6.8, H-5), 4.842 (1H, m,
H-6), 5.78 (1H, d, J = 9.9, H-7), 5.95 (1H, m, H-8), 6.00
(1H, m, H-9), 2.96, 3,73 (1H, d, J = 18.1, H-10), 3.20 (3H,
s, H-11). 13C NMR spectrum (DMSO-d6, 100 MHz):
166.0 (C-1), 77.2 (C-3), 60.5 (C-3), 165.2 (C-4), 69.8 (C-5),
75.6 (C-6), 129.9 (C-7), 123.4 (C-8), 120.2 (C-9), 130.7
(C-19a), 36.6 (C-10), 73.1 (C-10a), 27.5 (C-11). LREI-MS
m/z: 349 [M]+ (C21H23N3O2). LREI-MS m/z: 326.38 [M]
+
(C13H14N2O4 S2).
Human fibrosarcoma cells (HT1080) were obtained
from the Korean Cell Line Bank (KCLB, Seoul, Korea).
Cells were cultured in DMEM supplemented with peni-
cillin/streptomycin and fetal bovine serum (FBS) (Gibco
BRL, Life Technology, NY, USA). Cytotoxicity assays
were performed with 3-(4,5-dimethyl-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) reagent (Sigma Chemical
Co., St. Louis, MO, USA). All antibodies used for
western blot analysis were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Other
chemicals and reagents were of commercially available
analytical grade.
Cell culture and cell viability assay
HT1080 cells were cultured on DMEM (Gibco, USA)
containing 10 % FBS and incubated at 37 °C under a
humidified atmosphere of 5 % CO2. Cytotoxicity of glio-
toxin on HT1080 cells was analyzed using an MTT
assay. To estimate the cytotoxicity of gliotoxin, cells
were seeded in a 96-well plate at a concentration of 4 ×
104 cells/ml and incubated for 24 h. The cells were thenexposed to different concentrations (0, 25, 50, or
100 μM) of gliotoxin at 37 °C under a humidified atmos-
phere of 5 % CO2. Subsequently, 100 μl MTT solution
(1 mg/ml) was added to each well, and cells were incu-
bated for another 3 h. The formazan salt that formed
was dissolved in 100 μl DMSO. The absorbance was
measured at 550 nm (GENiosr Microplate Reader, Tecan
Austria GmbH, Austria).
Annexin V/propidium iodide (PI) assay
Apoptotic cells were stained using the fluorescence
isothiocyanate (FITC) Annexin V apoptosis detection
kit (BD Biosciences) according to the manufacturer’s
instructions. Briefly, HT1080 cells were cultured in
6-well plates at a density of 5 × 104 cells/ml. The cells
were then treated with 100 μM gliotoxin for 24 h.
After incubation, trypsinized, floating, and adherent
cells were pooled and centrifuged. Harvested cells were
washed with PBS twice, mixed in 1× binding buffer,
and incubated with Annexin V/PI double-staining
solution at room temperature (RT) for 20 min.
The stained cells were analyzed by flow cytometry
(FACSCalibur, BD Science, Heidelberg, Germany), and
the percentage of apoptotic cells was calculated using
Cell Quest software.
Extraction of cellular proteins
After the indicated incubation times with or without
100 μM gliotoxin, HT1080 cells were lysed. Nuclear and
cytoplasmic extracts were prepared according to Duvoix
et al. (2004). Briefly, cell pellets were suspended in ice-
cold hypotonic lysis buffer containing protease inhibi-
tors. We added 10 % Igepal (Sigma-Aldrich) to the cell
suspension and vortexed for 10 s to lyse the cells. The
lysate was then centrifuged at 18,000 rpm for 1 min.
The cytoplasmic supernatant was stored, and cell pellets
were washed with hypotonic lysis buffer. Nuclear extrac-
tion buffer was added to each pellet, and the cell suspen-
sion was gently mixed on an orbital shaker for 15 min at
4 °C. This was followed by centrifugation at 10,500 rpm
for 7 min at 4 °C. Finally, the nuclear supernatant was
transferred to a prechilled microcentrifuge tube and
stored at −80 °C.
Western blot analysis
Western blotting was performed according to the stand-
ard procedures. Briefly, cells were cultured at a density
of 5 × 104 cells/ml in six-well plates with serum-free
media. After incubation for 24 h, cells were treated with
gliotoxin for another 24 h. Cells were lysed in RIPA
(150 mM NaCl, 1.0 % IGEPAL® 0.5 % sodium deoxycho-
late, 0.1 % sodium dodecylsulfate, 50 mM Tris, pH 8.0)
buffer at 4 °C for 30 min. Proteins from nuclear and
cytoplasmic extracts were obtained, and 100 μg/ml of
Fig. 1 Gliotoxin decreases proliferation of HT1080 human fibrosarcoma
cells. HT1080 cells were treated with various concentrations (0 to
100 μM) of gliotoxin for 24 h. Cell viability was determined by MTT
assay. Each value is expressed as the mean ± standard deviation
(SD) of three independent experiments. *P < 0.05 compared to the
control group (0 μM)
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sulfate-polyacrylamide gel electrophoresis with a 5 %
stacking gel. Separated proteins were transferred onto a
nitrocellulose membrane (Amersham Pharmacia Bio-
tech, England, UK). The membrane was blocked for
1.5 h at RT using Tris-buffered saline and 0.1 %
Tween-20 (TBS-T) with 5 % skim milk. After washing
the membrane with TBS-T twice, the blots were incubated
for 1 h with the indicated antibodies at 25 °C. The
respective proteins were detected with a chemilumines-
cent ECL assay kit (Amersham Pharmacia, England, UK)
according to the manufacturer’s instructions.
Measurement of ROS
HT1080 cells (2 × 105 cells) were incubated with or without
100 μM gliotoxin for 24 h. Cellular ROS levels were deter-
mined by staining with dihydroethidium (DHE) (Sigma-
Aldrich) and by using the Muse Oxidative Stress Kit
(Millipore) according to the manufacturer’s instructions.
Statistical analysis
Data were analyzed using the InStat statistics program
(GraphPad Software, Inc., San Diego, CA, USA). Statis-
tical comparisons were performed using one-way ana-
lysis of variance (ANOVA) with the Bonferroni test for
multiple comparisons.
Results
To examine the antiproliferative effects of gliotoxin on
human HT1080 fibrosarcoma cells, we treated cultures
with various concentrations of gliotoxin (0–100 μM) for
24 h. The antiproliferative effects were assessed by a
colorimetric MTT assay. Gliotoxin treatment decreased
the number of viable cells in a dose-dependent manner
(Fig. 1). This suggested that gliotoxin decreased prolifer-
ation of HT1080 cells, and it may have generally cyto-
toxic effects.
To determine whether the antiproliferative effect of
gliotoxin was associated with apoptotic cell death,
HT1080 cells were treated with 100 μM gliotoxin for
24 h. Cells were then double stained with Annexin V
and propidium iodide (PI), and flow cytometric analyses
were performed (Fig. 2). The percentage of Annexin V-
positive and PI-positive cells presenting in late-apoptosis
phase increased from 33.7 to 68.7 % after treatment with
gliotoxin. This clearly indicates that gliotoxin induced
apoptosis in HT1080 cells.
NF-κB induces expression of several genes that
promote malignant properties associated with tumor
growth and inhibit apoptosis (Panwalkar et al. 2004).
Constitutive activation of NF-κB has been shown in
several types of cancer (Sasaki et al. 2001; Weichert
et al. 2007; Sakamoto et al. 2009). In unstimulated cells,
NF-κB is typically sequestered in the cytoplasm whereit complexes with inhibitors such as IκB-α. When cells
experience the proper stimulus, cytoplasmic NF-κB be-
comes activated primarily through phosphorylation and
degradation of IκB-α. NF-κB then translocates from the
cytosol to the nucleus and induces expression of target
genes (Siebenlist et al. 1994; Baeuerle and Baltimore 1996).
To examine the effects of gliotoxin on NF-κB signal-
ing, we analyzed the expression and phosphorylation
state of IκB-α. We also investigated the expression of
NF-κB and the nuclear translocation dynamics of the
p65 subunit after gliotoxin treatment (Fig. 3). HT1080
cells were cultured with gliotoxin (0–100 μM) for 24 h,
and the cytosol and nuclear lysates were each subjected
to western blot analysis. Treatment with gliotoxin inhib-
ited NF-κB activation. High levels of NF-κB-p65 were
found in nuclear fraction of control HT1080 cells with-
out gliotoxin treatment. However, exposure to gliotoxin
decreased the amount of nuclear-localized NF-κB-p65.
Gliotoxin treatment also reduced phosphorylation of
IκB-α and increased overall expression of IκB-α. To-
gether, these results suggest that gliotoxin inhibited the
nuclear import and activation of NF-κB by suppressing
the phosphorylation and subsequent degradation of its
inhibitor, IκB-α.
ROS are produced by a variety of cellular processes.
This oxidative stress response frequently triggers apop-
totic cell death (Russell and cotter 2015). One reason
for this is the inhibition of NF-κB activity by ROS,
which ultimately enhances apoptosis. Specifically, ROS
inhibit DNA binding of NF-κB through direct oxidation
of NF-κB (Toledano and Leonard 1991; Nowak et al.
2008) and through the modification of its inhibitor,
Fig. 2 Gliotoxin induces apoptosis of HT1080 cells. HT1080 cells were treated with 100 μM gliotoxin for 24 h and analyzed by Annexin V/PI
staining. Gliotoxin increased the cell population occupying the Annexin V/PI double-positive quadrant (UR upper right), which represents
late-apoptotic cells
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fluenced ROS levels in HT1080 cells. After treating
cells with 100 μM gliotoxin, ROS levels increased
from 32.2 to 62.7 % compared to untreated controls
(Fig. 4). Taken together, these results suggest that
gliotoxin triggered apoptotic cell death in HT1080
cells via generation of ROS and inactivation of NF-κB
signaling.Fig. 3 Gliotoxin inhibits activation of NF-κB by suppressing the phosphoryl
concentrations (0 to 100 μM) of gliotoxin for 24 h, and the cytosol and nuc
NF-κB, phosphorylated IκB-α, total IκB-α, α-tubulin, and lamin B (a). The imm
mean ± SD of a triplicate experiment. *P < 0.05 compared to the control wiDiscussion
Apoptosis is a process of programmed cell death that
occurs in multicellular organisms. The development and
progression of cancer frequently involves the suppression
of apoptosis. Therefore, almost all cytotoxic anticancer
therapies currently in clinical use attempt to target cancer
cells by inducing apoptosis. The NF-κB pathway is in-
volved in tumorigenesis, tumor cell proliferation, andation and degradation of IκB-α. HT1080 cells were treated with various
lear lysates were subjected to immunostaining for the p65 subunit of
unoblot signals were quantified. Each value was expressed as the
thout gliotoxin treatment (b)
Fig. 4 Gliotoxin increases intracellular ROS. HT1080 cells were treated
with or without 100 μM gliotoxin for 24 h. ROS (−)/(+) cell count were
determined by dihydroethidium (DHE) staining and by the Muse
analyzer oxidative stress kit. Results of at least three independent
experiments were averaged. All data are presented as the mean ± SD.
*P < 0.05 compared to the ROS (−) without gliotoxin treatment
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For example, constitutive activation of NF-κB has been
reported in several types of cancers including gastric
cancer, pancreatic cancer, and colorectal carcinoma
(Sasaki et al. 2001; Weichert et al. 2007; Sakamoto et al.
2009). NF-κB helps activate downstream proteins that
promote tumor growth and inhibit apoptosis in tumor
cells. Given the antiapoptotic effects of NF-κB, inhibi-
tors of NF-κB are promising antitumor drugs. As a re-
sult, much effort has focused on developing inhibitors
that target NF-κB (Yemelyanov et al. 2006; Yang et al.
2006). Recently, ROS have been also reported to repress
NF-κB signaling in many ways. Direct oxidation of NF-
κB by ROS inhibits its DNA-binding ability (Toledano
and Leonard 1991). ROS modification of IκB-α leads to
inhibition of NF-κB signaling (Nowak et al. 2008). In
addition, ROS stabilize IκB-α by inhibiting the prote-
asome, resulting in downregulation of NF-κB signaling
(Wu et al. 2009). Therefore, it seems reasonable that
ROS function as physiological signaling modulators of
NF-κB signaling cascades in cancers. Our results support
this hypothesis. We showed that gliotoxin, a natural com-
pound isolated from the marine fungus A. fumigatus,
inhibited proliferation and induced apoptosis in human
HT1080 fibrosarcoma cells by increasing intracellular
ROS levels and repressing activation and nuclear trans-
location of NF-κB. Therefore, we suggest that gliotoxin
may constitute a promising new antitumor drug for the
targeted inhibition of NF-κB signaling.
Conclusions
We demonstrated that gliotoxin, a mycotoxin produced
by the marine fungus A. fumigatus, induced apoptosis inHT1080 human fibrosarcoma cells. It achieved this, at
least in part, through an increase in levels of intracellular
ROS and repression of NF-κB signaling. Cumulatively,
our results provide a new avenue of research into the
design and development of NF-κB antagonists for the
treatment of cancer.
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